PCH
MNPR icon

Polar Capital Holdings’s Monopar Therapeutics MNPR Stock Holding History

Polar Capital Holdings’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Buy
226,526
+120,776
+114% +$7.3M 0.04% 173
2025
Q4 		$6.91M Buy
+105,750
New +$8.64M 0.03% 217

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Polar Capital Holdings's MNPR Position: Q1 2026 in Review

Polar Capital Holdings increased its Monopar Therapeutics (MNPR) stake by 114% in Q1 2026, buying an estimated $7.3M and bringing the position to 226,526 shares worth $12.4M. The position accounts for 0.04% of the portfolio, ranked #173.

Polar Capital Holdings first reported a position in MNPR in Q4 2025 and has held it in 2 quarters since. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Polar Capital Holdings held 226,526 shares of Monopar Therapeutics worth $12.4M as of Q1 2026.
  • Polar Capital Holdings bought 120,776 Monopar Therapeutics shares in Q1 2026, an estimated $7.3M.
  • Monopar Therapeutics made up 0.04% of Polar Capital Holdings's portfolio in Q1 2026, its #173 holding.
  • Polar Capital Holdings first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.